The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity
Immune checkpoint blockade has demonstrated success in treating cancer but can lead to
immune-related adverse events (irAEs), illustrating the centrality of these pathways in …
immune-related adverse events (irAEs), illustrating the centrality of these pathways in …
[HTML][HTML] A snapshot of the PD-1/PD-L1 pathway
Cancer cells can evade the attack from host immune systems via hijacking the regulatory
circuits mediated by immune checkpoints. Therefore, reactivating the antitumor immunity by …
circuits mediated by immune checkpoints. Therefore, reactivating the antitumor immunity by …
[HTML][HTML] Rethinking immune checkpoint blockade:'Beyond the T cell'
X Liu, GD Hogg, DG DeNardo - Journal for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
The clinical success of immune checkpoint inhibitors has highlighted the central role of the
immune system in cancer control. Immune checkpoint inhibitors can reinvigorate anti-cancer …
immune system in cancer control. Immune checkpoint inhibitors can reinvigorate anti-cancer …
The paradoxical roles of inflammation during PD-1 blockade in cancer
M Hill, M Segovia, S Russo, MR Girotti… - Trends in …, 2020 - cell.com
Recent studies have reported paradoxical roles of inflammation in tumor immunity triggered
by PD-1 checkpoint antibody (Ab) blockade. Here, we elaborate on this controversy and …
by PD-1 checkpoint antibody (Ab) blockade. Here, we elaborate on this controversy and …
[HTML][HTML] PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome
Several cancers are highly refractory to conventional chemotherapy. The survival of tumors
in several cases is assisted by checkpoint immunomodulation to maintain the imbalance …
in several cases is assisted by checkpoint immunomodulation to maintain the imbalance …
Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
The programmed death-1 receptor (PD-1) acts as a T-cell brake, and its interaction with
ligand-1 (PD-L-1) interferes with signal transduction of the T-cell receptor. This leads to …
ligand-1 (PD-L-1) interferes with signal transduction of the T-cell receptor. This leads to …
Recent advances in the clinical development of immune checkpoint blockade therapy
A Ghahremanloo, A Soltani, SMS Modaresi… - Cellular Oncology, 2019 - Springer
Background The discovery of immune checkpoint proteins and the mechanisms by which
cancer cells utilize them to evade the immune system has transformed our approach to …
cancer cells utilize them to evade the immune system has transformed our approach to …
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
S Kumagai, Y Togashi, T Kamada, E Sugiyama… - Nature …, 2020 - nature.com
Immune checkpoint blockade has provided a paradigm shift in cancer therapy, but the
success of this approach is very variable; therefore, biomarkers predictive of clinical efficacy …
success of this approach is very variable; therefore, biomarkers predictive of clinical efficacy …
[HTML][HTML] PD-1–PD-L1 axis: efficient checkpoint blockade against cancer
A Errico - Nature reviews Clinical oncology, 2015 - nature.com
Cancer immunotherapy is presently one of the areas in which major medical breakthroughs
are being witnessed, with impressive results reported by several groups. Recently, three …
are being witnessed, with impressive results reported by several groups. Recently, three …
Immune checkpoint blockade in cancer immunotherapy: mechanisms, clinical outcomes, and safety profiles of PD-1/PD-L1 inhibitors
Programmed cell death protein 1 (PD-1) and its ligand PD-L1 are critical for the regulation of
T cell exhaustion and activity suppression. Tumor cells expressing immune checkpoints …
T cell exhaustion and activity suppression. Tumor cells expressing immune checkpoints …